Urology
Volume 73, Issue 2 , Pages 363-368 , February 2009

PCA3 Urine mRNA Testing for Prostate Carcinoma: Patterns of Use by Community Urologists and Assay Performance in Reference Laboratory Setting

  • Scott B. Shappell

      Affiliations

    • Molecular Oncology Diagnostic Laboratory, Dallas, Texas
    • Corresponding Author InformationReprint requests: Scott B. Shappell, M.D., Ph.D., Mosaic Diagnostics, 6060 North Central Expressway, Suite 262, Dallas TX 75206
    • ,
  • John Fulmer

      Affiliations

    • Molecular Oncology Diagnostic Laboratory, Dallas, Texas
    • ,
  • David Arguello

      Affiliations

    • Molecular Profiling Institute, Phoenix, Arizona
    • ,
  • Brian S. Wright

      Affiliations

    • Molecular Profiling Institute, Phoenix, Arizona
    • ,
  • Jonathan R. Oppenheimer

      Affiliations

    • Oppenheimer Urologic Reference Laboratory, Nashville, Tennessee
    • ,
  • Mathew J. Putzi

      Affiliations

    • Oppenheimer Urologic Reference Laboratory, Nashville, Tennessee

Received 23 April 2008 ,Accepted 4 August 2008.

References 

  1. Wilson SS, Crawford ED. Screening for prostate cancer: Current recommendations. Urol Clin North Am. 2004;31:219–226
  2. Thompson IM, Bermejo C, Hernandez J, et al. Screening for prostate cancer: Opportunities and challenges. Surg Oncol Clin North Am. 2005;14:747–760
  3. Shappell SB. Clinical utility of prostate carcinoma molecular diagnostic tests. Rev Urol. 2008;10:44–69
  4. Bussemakers MJG, van Bokhoven A, Verhaegh GW, et al. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975–5979
  5. de Kok JB, Verhaegh GW, Roelofs RW, et al. DD3PCA3, a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–2698
  6. Hessels D, Klein Gunnewiek JMT, van Oort I, et al. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8–16
  7. Tinzl M, Marberger M, Horvath S, et al. DD3(PCA3) RNA analysis in urine—A new perspective for detecting prostate cancer. Eur Urol. 2004;46:182–187
  8. Fradet Y, Saad F, Aprikian A, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64:311–315
  9. Groskopf J, Aubin SM, Deras IL, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089–1095
  10. van Gils MPMQ, Hessels D, van Hooij O, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007;13:939–943
  11. Marks LS, Fradet Y, Deras IL, et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology. 2007;69:532–535
  12. Epstein JI, Chan DW, Sokoll LJ, et al. Nonpalpable stage T1c prostate cancer: Prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol. 1998;160:2407–2411
  13. Deras IL, Aubin SM, Blase A, et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587–1592
  14. Nakanishi H, Groskopf J, Fritsche HA, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol. 2008;179:1804–1810
  15. Epstein JI, Herawi M. Prostate needle biopsies containing prostatic intraepithelial neoplasia or atypical foci suspicious for carcinoma: Implications for patient care. J Urol. 2006;175:820–834
  16. Girasole CR, Cookson MS, Putzi MJ, et al. Significance of atypical and suspicious small acinar proliferations, and high grade prostatic intraepithelial neoplasia on prostate biopsy: Implications for cancer detection and biopsy strategy. J Urol. 2006;175:929–933
  17. Djavan B, Remzi M, Marberger M. When to biopsy and when to stop biopsying. Urol Clin North Am. 2003;30:253–262
  18. Presti JCJ. Prostate biopsy strategies. Nat Clin Pract Urol. 2007;4:505–511
  19. Griffin CR, Yu X, Loeb S, et al. Pathological features after radical prostatectomy in potential candidates for active monitoring. J Urol. 2007;178:860–863
  20. Popa I, Fradet Y, Beaudry G, et al. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol. 2007;20:1121–1127

PII: S0090-4295(08)01431-3

doi: 10.1016/j.urology.2008.08.459

Urology
Volume 73, Issue 2 , Pages 363-368 , February 2009

Article Tools

* Image Usage & Resolution